Amgen Inc. Files Definitive Proxy Statement (DEF 14A)

Ticker: AMGN · Form: DEF 14A · Filed: Apr 17, 2024 · CIK: 318154

Amgen INC DEF 14A Filing Summary
FieldDetail
CompanyAmgen INC (AMGN)
Form TypeDEF 14A
Filed DateApr 17, 2024
Risk Level
Pages15
Reading Time18 min
Key Dollar Amounts$27.8 billion, $4.8 billion, $1.1 billion, $4.6 billion, $96 m
Sentimentneutral

Sentiment: neutral

Topics: Amgen, DEF 14A, Proxy Statement, Executive Compensation, Shareholder Meeting

TL;DR

<b>Amgen Inc. has filed its Definitive Proxy Statement (DEF 14A) for the fiscal year ending December 31, 2023.</b>

AI Summary

AMGEN INC (AMGN) filed a Proxy Statement (DEF 14A) with the SEC on April 17, 2024. Amgen Inc. filed a Definitive Proxy Statement (DEF 14A) on April 17, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at One Amgen Center Drive, Thousand Oaks, CA 91320. Amgen Inc. is incorporated in Delaware. The filing includes data related to executive compensation for the fiscal years 2020, 2021, and 2022.

Why It Matters

For investors and stakeholders tracking AMGEN INC, this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation structures and company governance decisions before the annual meeting. The DEF 14A provides detailed information on how the company is managed and how executive pay is determined, impacting investor confidence and proxy voting.

Risk Assessment

Risk Level: — AMGEN INC shows moderate risk based on this filing. The filing is a routine proxy statement (DEF 14A) and does not contain new financial performance data or significant strategic shifts, indicating a low level of immediate risk.

Analyst Insight

Review the executive compensation details and any proposed shareholder resolutions within the DEF 14A to inform proxy voting decisions.

Key Numbers

Key Players & Entities

FAQ

When did AMGEN INC file this DEF 14A?

AMGEN INC filed this Proxy Statement (DEF 14A) with the SEC on April 17, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by AMGEN INC (AMGN).

Where can I read the original DEF 14A filing from AMGEN INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by AMGEN INC.

What are the key takeaways from AMGEN INC's DEF 14A?

AMGEN INC filed this DEF 14A on April 17, 2024. Key takeaways: Amgen Inc. filed a Definitive Proxy Statement (DEF 14A) on April 17, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company's principal executive offices are located at One Amgen Center Drive, Thousand Oaks, CA 91320..

Is AMGEN INC a risky investment based on this filing?

Based on this DEF 14A, AMGEN INC presents a moderate-risk profile. The filing is a routine proxy statement (DEF 14A) and does not contain new financial performance data or significant strategic shifts, indicating a low level of immediate risk.

What should investors do after reading AMGEN INC's DEF 14A?

Review the executive compensation details and any proposed shareholder resolutions within the DEF 14A to inform proxy voting decisions. The overall sentiment from this filing is neutral.

How does AMGEN INC compare to its industry peers?

Amgen operates in the biotechnology and pharmaceutical industry, focusing on the discovery, development, manufacturing, and marketing of human therapeutics.

Are there regulatory concerns for AMGEN INC?

The DEF 14A filing is a requirement under the Securities Exchange Act of 1934, mandating public companies to provide shareholders with information regarding annual meetings and related matters.

Industry Context

Amgen operates in the biotechnology and pharmaceutical industry, focusing on the discovery, development, manufacturing, and marketing of human therapeutics.

Regulatory Implications

The DEF 14A filing is a requirement under the Securities Exchange Act of 1934, mandating public companies to provide shareholders with information regarding annual meetings and related matters.

What Investors Should Do

  1. Review the executive compensation tables for PEO and Non-PEO NEOs for fiscal years 2020-2022.
  2. Examine any proposals presented for shareholder vote, such as director elections or advisory resolutions on executive compensation.
  3. Note the company's stated fiscal year end of December 31st.

Key Dates

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for annual meetings and does not represent a change from previous filings in terms of its nature, but provides updated information for the current reporting period.

Filing Stats: 4,405 words · 18 min read · ~15 pages · Grade level 13.9 · Accepted 2024-04-17 16:02:24

Key Financial Figures

Filing Documents

Executive Compensation Tables

Executive Compensation Tables 83 Pay Versus Performance 100 Director Compensation 103 Item3—Approval of Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan 108

Security Ownership of Directors and Executive Officers

Security Ownership of Directors and Executive Officers 118

Security Ownership of Certain Beneficial Owners

Security Ownership of Certain Beneficial Owners 120 Securities Authorized for Issuance Under Existing Equity Compensation Plans 121 Item4—Ratification of Selection of Independent Registered Public Accountants 123 Audit Matters 124 Annual Report on Form 10-K 125 Certain Relationships and Related Transactions 126 Information Concerning Voting and Solicitation 128 Other Matters 133 Appendix A: Amgen Inc. Board of Directors Guidelines for Director Qualifications and Evaluations A-1 Appendix B: Reconciliations of GAAP to Non-GAAP Measures B-1 Appendix C: Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan C-1 2024 Proxy Statement Proxy Statement Summary Proxy Statement Summary This summary contains highlights about our Company and the upcoming 2024 Annual Meeting of Stockholders, or Annual Meeting. This summary does not contain all of the information that you should consider in advance of the meeting and we encourage you to read the entire proxy statement before voting. 2024 Annual Meeting of Stockholders Date and Time: Friday, May 31, 2024, at 11:00 A.M., Pacific Time Location: Our 2024 Annual Meeting of Stockholders will be held solely by remote communication via the internet at www.virtualshareholdermeeting.com/AMGN2024 . Although the meeting will not be held in person, stockholders will, to the extent possible, be afforded the same rights and opportunities to participate at the virtual meeting similarly to how they would participate at an in-person meeting. Stockholders or their proxyholders may participate and vote at our Annual Meeting via the internet at www.virtualshareholdermeeting.com/AMGN2024 and using your control number. Record Date: April 1, 2024 Mail Date: We intend to mail the Notice Regarding the Availability of Proxy Materials, or Notice, or the proxy statement and proxy card, as applicable, on or about April 17, 2024, to our stockholders. Voting Matters and Board Recommendatio

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing